Media Center

Recent News

09/26/18ACADIA Pharmaceuticals Announces Executive Appointments to Lead Medical Affairs and SciencePrinter Friendly Version
09/25/18ACADIA Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference on October 2, 2018Printer Friendly Version
09/20/18FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease PsychosisPrinter Friendly Version
09/10/18Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimer’s Disease Psychosis and Parkinson’s Disease Psychosis Published in The Journal of Prevention of Alzheimer’s Disease Suggest Potential for Treating Dementia-Related PsychosisPrinter Friendly Version
09/04/18ACADIA Pharmaceuticals to Present at the Morgan Stanley 16th Annual Global Healthcare Conference on September 13, 2018Printer Friendly Version
2018 | 2017 | 2016 | Archive

Company Information

Annual Report


Scientific Publications

Pimavanserin for patients with Parkinson's disease psychosis: a randomized, placebo-controlled phase 3 trial. The Lancet, 383, 533-540 (2014).